Due to the advantages of subclinical phase identification and complementarity with left ventricular ejection fraction assessment, the speckle-tracking echocardiography represented by GLS measurement has gradually entered clinical practice in the field of chemotherapy-related cardiotoxicity. In research, novel parameters, non-LV evaluation, myocardial work measurement and other related studies have shown advances in speckle-tracking echocardiography. This article summarizes the above-mentioned advances, limitations, and future development directions of the speckle-tracking echocardiography.